T1	Participants 819 944	postmenopausal women with advanced breast carcinoma who had disease progression after receipt of previous endocrine treatment
T2	Participants 1025 1095	319 (74.5%) patients in the fulvestrant group and 322 (76.1%) patients
T3	Participants 1185 1245	10-20% of patients still alive > 5 years after randomization
T4	Participants 1360 1388	anastrozole-treated patients
T5	Participants 1781 1832	postmenopausal women with advanced breast carcinoma
